The influence of MTHFR C677T polymorphism on methotrexate toxicity in pediatric acute lymphoblastic leukemia

Authors

  • Билјана (Biljana) Чонеска-Јованова (Choneska-Jovanova) Универзитетска клиника за детски болести Скопје (University Clinic for Children's Diseases, Skopje)
  • Соња (Sonja) Алабаковска (Alabakovska) Институт за медицинска и експериментална биохемија, Медицински Факултет, Универзитет Св. Кирил и Методиј Скопје (Institute for medical and experimental biochemistry, Medical Faculty, University Sts Ciril and Methodius Skopje)
  • Ката (Kata) Мартинова (Martinova) Универзитетска клиника за детски болести Скопје (University Clinic for Children's Diseases, Skopje)
  • Сашо (Sasho) Панов (Panov) Институт за биологија Факултет за природни науки, Универзитет Св Кирил и Методиј, Скопје (Institute of Biology, Faculty of Sciences, Ss. Cyril and Methodius university Skopje)
  • Зорица (Zorica) Антевска Трајкова (Antevska Trajkova) Универзитетска клиника за детски болести Скопје (University Clinic for Children's Diseases, Skopje)
  • Светлана (Svetlana) Кочева (Kocheva) Универзитетска клиника за детски болести Скопје (University Clinic for Children's Diseases, Skopje)
  • Александра (Аleksandra) Јовановска (Jovanovska) Универзитетска клиника за детски болести Скопје (University Clinic for Children's Diseases, Skopje)

Keywords:

acute lymphoblastic leukemia, methotrexate, toxic effects, MTHFR, polymorphisms

Abstract

In current protocols for treatment of acute lymphoblastic leukemia in childhood methotrexate (MTX) is one of the crucial cytostatics. The occurrence of MTX toxicity is still  Ð° great problem because of the interpatient differences in drug metabolism. These differences may  be due  to polymorphisms of genes involved in the folate metabolism. The present study was carried out to determine the prevalence of MTHFR  C677T polymorphism in children with acute lymphoblastic leukemia (ALL). Also the effect of the genotype on the toxic  effects during therapy with high doses of МТХ in 45 patients with ALL treated in accordance with the protocol ALL BFM 95 and ALL BFM 2000 was evaluated. All 45 patients with ALL were genotyped for MTHFR C677T polymorphism. Correlation with the presence of a certain polymorphism and toxic effects of the chemotherapy with high doses of МТХ was  made in the Department  for hematology and oncology at the University Clinic for children's diseases – Skopje. The control group included 32 healthy patients. In the study group 24 (53.3%) children had a wild type of polymorphism (CC), 15 (33.33%) children were heterozygous (CT) for MTHFR C677T polymorphism, and 6 (13.33%) children were homozygous for the variant type  of the polymorphism (ТТ). The  correlation of the genotype with МТХ toxicity indicated a statistical significance only for oral mucositis, while for the other toxic effects there was no statistically significant correlation. In our study the results indicated that oral mucositis was statistically significantly more frequently identified in the case of the variant carriers for this polymorphism. For the other toxic effects caused by the therapy with high doses of МТХ no statistically  significant correlation with MTHFR C677T polymorphism was  identified. This  occurrence maybe due  to the small number of patients analyzed in this study and the possible protective influence of other genetic polymorphisms included in the folate metabolism, which were not subject to consideration of this study.

Downloads

Download data is not yet available.

Author Biography

Сашо (Sasho) Панов (Panov), Институт за биологија Факултет за природни науки, Универзитет Св Кирил и Методиј, Скопје (Institute of Biology, Faculty of Sciences, Ss. Cyril and Methodius university Skopje)

Molecular Biology and Genetics Dpt.

References

Mí¶ricke A, Reiter A, Zimmermann M et al. Risk - adjusted

therapy of acute lymphoblastic leukemia can decrease

treatment burden and improve survival: treatment

results of 2169 unselected pediatric and adolescent

patients enrolled in the trial ALL-BFM 95. Blood

; 111 (9): 4477-89.

Schmiegelow K. Advances in individual prediction of

methotrexate toxicity: a review. Br J

Haematol 2009; 146:489–503.

Giovannetti E, Ugrasena DG, Supriyadi E et al. Methylenetetrahydrofolate

reductase (MTHFR) C677T and thymidylate

synthase promoter (TSER) polymorphisms in

Indonesian children with and without leukemia. Leuk

Res 2008; 32: 19–24.

Binia A, Contreras A, Canizales-Quinteros S. Geographical

and ethnic distribution of single nucleotide polymorphisms

within genes of the folate/homocysteine

pathway metabolism. Genes Nutr 2014; 9(5):421.

Chiusolo P, Reddiconto G, Casorelli I et al. Preponderance

of methylenetetrahydrofolate reductase C677T

homozygosity among leukemia patients intolerant to

methotrexate. Ann Oncol 2002;13(12):1915-18.

Lopez-Lopez E1, Martin-Guerrero I, Ballesteros J, Garcia-

Orad A. A systematic review and meta-analysis of

MTHFR polymorphisms in methotrexate toxicity prediction

in pediatric acute lymphoblastic leukemia. Pharmacogenomics

J 2013;13(6):498-506.

Schrappe M, Reiter A, Zimmerman M et al.: Long term

results of four consecutive trials in childhood ALL performed

by ALL-BFM study group from1981-1995. Leukemia

;14 (12):2205-22.

Fukushima H, Fukushima T, Sakai A et al., et al. Polymorphisms

of MTHFR Associated with Higher Relapse/

Death Ratio and Delayed Weekly MTX Administration

in Pediatric Lymphoid Malignancies. Leuk Res Treatment

; Article ID 238528,

http://dx.doi.org/10.1155/2013/238528.

Yang L, Hu X, Xu L. Impact of methylenetetrahydrofolate

reductase (MTHFR) polymorphisms on methotrexate-

induced toxicities in acute lymphoblastic leukemia:

a meta-analysis. Tumor Biology 2012; 33(5):

-54.

Shimasaki N, Mori T, Samejima H et al. Effects of methylenetetrahydrofolate

reductase and reduced folate

carrier 1 polymorphisms on high-dose methotrexateinduced

toxicities in children with acute lymphoblastic

leukemia or lymphoma. J Pediatr Hematol Oncol

;28(2):64-8.

Seidemann K, Book M, Zimmermann M et al. MTHFR

(C"”>T) polymorphism is not relevant for prognosis

or therapy-associated toxicity in pediatric NHL: results

from 484 patients of multicenter trial NHL-BFM

Ann Hematol 2006;85: 291-300.

Faganel Kotnik B, Grabnar I, Bohanec Grabar P,

Dolžan V, Jazbec J. Association of genetic polymorphism

in the folate metabolic pathway with methotrexate

pharmacokinetics and toxicity in childhood

acute lymphoblastic leukaemia and malignant

lymphoma. Eur J Clin Pharmacology 2011;

(10):993-1006.

Krajinovic M, Lamothe S, Labuda D et al. Role of

MTHFR genetic polymorphisms in the susceptibility to

childhood acute lymphoblastic leukemia. Blood 2004;

(1): 252-7

Evans WE, Crews K R and Pui C-H. A Health-Care System

Perspective on Implementing Genomic Medicine:

Pediatric Acute Lymphoblastic Leukemia as a Paradigm.

Clin Pharmacol Ther 2013;94(2):224-9.

Costea I , Moghrabi A , Laverdiere C, Graziani

A, Krajinovic M. Folate Cycle Gene Variants And Chemotherapy

Toxicity In Pediatric Patients With Acute

Lymphoblastic Leukemia. Haematologica

; 91(8): 1113-16.

Downloads

Published

2017-07-01

How to Cite

1.
Чонеска-Јованова (Choneska-Jovanova) Билјана (Biljana), Алабаковска (Alabakovska) Соња (Sonja), Мартинова (Martinova) Ката (Kata), Панов (Panov) Сашо (Sasho), Антевска Трајкова (Antevska Trajkova) Зорица (Zorica), Кочева (Kocheva) Светлана (Svetlana), et al. The influence of MTHFR C677T polymorphism on methotrexate toxicity in pediatric acute lymphoblastic leukemia. Arch Pub Health [Internet]. 2017 Jul. 1 [cited 2026 Nov. 21];7(1):35-40. Available from: https://journals.mk/index.php/aph/article/view/953

Most read articles by the same author(s)

  • Билјана (Biljana) Чонеска-Јованова (Choneska-Jovanova), Ката (Kata) Мартинова (Martionva), Соња (Sonja) Алабаковска (Alabakovska), Зорица (Zorica) Антевска Трајкова (Antevska Trajkova), Костандина (Kostandina) Кузевска Манева (Kuzevska Maneva), Светлана (Svetlana) Кочева (Kocheva), Александра (Аleksandra) Јовановска (Jovanovska), Toxicities during therapy with high doses of methotrexate in children with acute lymphoblastic leukemia , Archives of Public Health: Vol. 7 No. 1 (2015): Archives of Public Health